2014 Fiscal Year Final Research Report
Studies about a radiosensitizer that is clinically usable
| Project/Area Number |
24591845
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 放射線治療 |
|---|
| Outline of Final Research Achievements |
An inhibitor of Poly (ADP-ribose) polymerase-1 (PARP-1), Olaparib enhanced sensitivity to radiation and Camptothecin (CPT) at low concentrations and after relatively short exposure times such as 2 h. The radiosensitizing effect of olaprib was not dependent on the p53 status of tumor cells. These characteristics could be advantageous for clinical radiotherapy since tumor cells may be exposed to low concentrations of olaparib and/or may have different levels of p53 mutation. The combination of olaparib and CPT had a stronger radiosensitizing effect, indicating that combining a PARP inihibitor with a topoiomerase I inhibitor could be promising for clinical radiosensitization.
|
| Free Research Field |
医歯学
|
